ALK Gene
Links shared publicly online about this topic
Dr. Li Discusses ALK Gene Mutation Tests
onclive.com — “Dr. Tianhong (Tina) Li from UC Davic Cancer Center Discusses ALK Gene Mutation Tests” View full resource at onclive.com
Most Recently Shared on August 29, 2011 at 6:46 pm By:
Dr. Tina Li from @UCD_Cancer Discusses ALK Gene Mutation Tests http://t.co/H0wC33i #lungcancer #onclivetv
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
medicalnewstoday.com — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients un” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2011 at 12:05 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene http://mnt.to/3Zf5 #healthnews
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
medicalnewstoday.com — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients un” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2011 at 5:16 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori ... http://t.co/UQkBTuN
Abbott Receives FDA Approval For ALK Gene Test For Lung Cancer Therapy Selection
medicalnewstoday.com — “Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2011 at 7:05 am By:
Abbott Receives FDA Approval For ALK Gene Test For Lung Cancer Therapy Selection http://mnt.to/3Zfn #genetics
Symposier - ASCO 2010: ALK Gene, Exciting News for Some Lung Cancer Patients
symposier.com — “Uploaded and shared in Youtube by: cancerconnect " Bruce Johnson, MD discusses the exciting new ALK gene clinical trial data benefiting a subset of lung cancer patients.” View full resource at symposier.com
Most Recently Shared on September 14, 2010 at 4:29 pm By:
Bruce Johnson, MD: ALK Gene, Exciting News for Some Lung Cancer Patients. http://bit.ly/cJz3Xf
Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy
news-medical.net — “Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.” View full resource at news-medical.net
Most Recently Shared on January 13, 2010 at 8:08 am By:
Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy: Results o... http://bit.ly/643oDx
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene - QualityPoint Technologies
qualitypointtech.net — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the Vysis ALK Break Apart FISH Probe Kit which detects the abnormal gene. The FDA has also approved this test. The abnormal ALK gene causes cancer to develop and grow. Approximately 1% to 7% of patients with non-small cell lung cancer have this genetic abnormality. They ar” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 1:45 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori (c... http://t.co/M9EhGbr
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene - QualityPoint Technologies
qualitypointtech.net — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the Vysis ALK Break Apart FISH Probe Kit which detects the abnormal gene. The FDA has also approved this test. The abnormal ALK gene causes cancer to develop and grow. Approximately 1% to 7% of patients with non-small cell lung cancer have this genetic abnormality. They ar” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 4:45 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori (c... http://t.co/IX8ESfO
ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug
news-medical.net — “A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital. The story highlights how scientific findings from St. Jude can be translated into therapies and tests that in addition to helping children, also help adults.” View full resource at news-medical.net
Most Recently Shared on September 30, 2011 at 1:46 pm By:
Lung Cancer News: ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug: A d... http://t.co/nav6CsKf
ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients
news-medical.net — “Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.” View full resource at news-medical.net
Most Recently Shared on July 1, 2010 at 7:18 am By:
Lung Cancer News: ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer pat... http://bit.ly/aEHE4T
Dr. Li Discusses the EML4-ALK Fusion Gene
onclive.com — “Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene” View full resource at onclive.com
Most Recently Shared on September 9, 2011 at 9:06 pm By:
Dr. Tianhong Li from @UCD_Cancer Discusses the EML4-ALK Fusion Gene http://t.co/YxuZe3g #OncLiveTV #lungcancer
Gene Testing Identifies Lung Cancer Patients Who Benefit From ALK-Inhibitor Drug
medicalnewstoday.com — “Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (alk) gene within the short arm of chromosome 2” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2010 at 5:38 pm By:
Gene Testing Identifies Lung Cancer Patients Who Benefit From ALK-Inhibitor Drug Results of a new study in non-small .. http://bit.ly/5l0l8r
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
medicalnewstoday.com — “Pfizer oncology announced today that it will initiate a global, phase 3 clinical trial of its investigational oral c-met and alk inhibitor, pf-02341066, versus standard of care chemotherapy in pat” View full resource at medicalnewstoday.com
Most Recently Shared on September 27, 2009 at 10:25 am By:
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Spe.. http://bit.ly/htlRM
FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection
news-medical.net — “Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.” View full resource at news-medical.net
Most Recently Shared on August 29, 2011 at 6:26 am By:
Breast Cancer News: FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection: Abbott today announce... http://t.co/FkNNCBP
Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC
news-medical.net — “The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.” View full resource at news-medical.net
Most Recently Shared on August 29, 2011 at 7:21 am By:
Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC: The U.S. Food and Drug Admi... http://t.co/6umNI8D
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
-
MNT Health News
Featured health news published by Medical News Today and chosen by the editorial team.
-
Lung Cancer OW
Organizing lung cancer resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
